Coulter Partners secures VP, Corporate Development & Strategy for Zumutor

Coulter Partners was delighted to partner with Zumutor Biologics, a leading Immuno-Oncology Company in the targeted NK cell therapeutics space, to secure the appointment of Ramon Valencia as Vice President, Corporate Development and Strategy. Ramon will help build on Zumutor’s key successes that include proprietary antibody discovery platforms and a compelling pipeline of molecules in NK Cell mediated immunotherapy.

Reporting to Zumutor’s CEO, Kavitha Iyer Rodrigues, Ramon is responsible for expanding the company’s mission primarily within big pharma clients. In addition, he is leading Zumutor’s strategic corporate development efforts, as well as in- and out-licensing for the current and future pipeline. Ramon has over 20 years’ experience in biotechnology, immuno-oncology (IO) and medical diagnostics, the last 14 of which have been focused on IO antibody research and business development, where he has executed multiple academic and industry research and licensing partnerships and collaborations.

Kavitha Iyer Rodrigues, CEO of Zumutor, says: “I welcome Ramon warmly to the team and thank Coulter Partners for their outstanding work in achieving this high-calibre appointment. Ramon brings valuable scientific and business development expertise to strengthen our leadership team at this important stage in Zumutor’s growth.”

About Zumutor Biologics:

Zumutor Biologics Inc. is a leading Immuno-oncology Company focusing on novel monoclonal antibody therapeutics against innate immunity targets. Zumutor’s high diversity human antibody libraries serve as a powerhouse for developing novel monoclonal antibody therapeutics targeting various immuno-oncology pathways. Their product pipeline constitutes unique immuno-oncotherapeutics that target innate immunity and regulate the tumor micro environment. Zumutor’s lead candidate in prostate cancer revealed significant tumor reduction when applied alone and in combination with checkpoint inhibitors in a mouse efficacy study. For more details, visit